Document Detail


Statins and endothelial dysfunction.
MedLine Citation:
PMID:  15861315     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The endothelium integrates and modulates critical functions of the arterial wall. As well as regulating vasomotion, it controls inflammation, coagulation, and thrombosis. Many of these actions are mediated through the release of nitric oxide. Endothelial dysfunction is associated with atherosclerosis and its risk factors. It is independently correlated to adverse cardiovascular events, including myocardial infarction, coronary death, and the need for revascularization. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) protect against cardiovascular death, myocardial ischemia, myocardial infarction, and stroke. Although cholesterol reduction accounts for some of these benefits, others appear to be independent of cholesterol lowering. The endothelium mediates many of these "lipid-dependent" and "lipid-independent" actions of statins. This chapter reviews the effects of statins on endothelial dysfunction. To do so, a brief outline of the biology of the endothelium is a prerequisite. This will be followed by a summary of the advances in vascular research on cholesterol-dependent and cholesterol-independent effects of statins, with a focus on the endothelium. Ultimately, clinical relevance of observations derived from basic biology will be discussed.
Authors:
Eric Larose; Peter Ganz
Related Documents :
11993305 - Prediction of coronary heart disease based on clinical suspicion, age, total cholestero...
18473965 - Is atorvastatin superior to other statins? analysis of the clinical trials with atorvas...
11796395 - High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens...
8900335 - Review of cholesterol-lowering therapy: coronary angiographic and events trials.
7073365 - Myocardial protection with cold blood potassium cardioplegia during prolonged aortic cr...
21705375 - Sensitive troponin assays.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Seminars in vascular medicine     Volume:  4     ISSN:  1528-9648     ISO Abbreviation:  Semin Vasc Med     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-04-29     Completed Date:  2005-08-18     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  100940307     Medline TA:  Semin Vasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  333-46     Citation Subset:  IM    
Affiliation:
Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteriosclerosis / etiology,  metabolism,  prevention & control
Blood Vessels / metabolism,  pathology,  physiopathology
Cholesterol / metabolism
Endothelium, Vascular / metabolism,  pathology,  physiopathology*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
Nitric Oxide Synthase / drug effects,  metabolism
Nitric Oxide Synthase Type III
Risk Factors
Vasoconstriction / drug effects,  physiology
Grant Support
ID/Acronym/Agency:
1 P50 HL 56985/HL/NHLBI NIH HHS; P50 HL 47743/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol; EC 1.14.13.39/NOS3 protein, human; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.14.13.39/Nitric Oxide Synthase Type III

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Statins and diabetes.
Next Document:  Lipid lowering therapy in atherosclerosis.